Hematology & Clinical Biochemistry & Family Medicine
Activated Partial Thromboplastin Time (aPTT).
The aPTT (activated partial thromboplastin time; formerly known as APTT or PTT) — is an in vitro coagulation test that measures the time required for a fibrin clot to form in citrated plasma after activation of the intrinsic coagulation pathway by a contact activator (kaolin + silica + celite) and the addition of cephalin (phospholipids) and calcium. It specifically assesses the intrinsic (contact) pathway of coagulation, involving factors XII + XI + IX + VIII (hemophilia A) + prekallikrein + high-molecular-weight kininogen, as well as the common pathway (factors X + V + II — prothrombin + I — fibrinogen), thereby enabling the detection of abnormalities in these factors or the presence of circulating inhibitors (lupus anticoagulant + acquired anti-factor VIII antibodies + unfractionated heparin). The normal APTT value is 25 to 38 seconds depending on the reagents and laboratories, and must always be interpreted relative to the control APTT (normal reference plasma) of the laboratory performing the test—an APTT is considered prolonged when it exceeds the control by more than 10 seconds (patient APTT/control APTT ratio > 1.2). The APTT is the standard monitoring parameter for treatment with unfractionated heparin (UFH)—maintaining the patient APTT/control ratio between 1.5 and 2.5 (depending on protocols)—, the screening tool for hemophilia A (factor VIII deficiency) and B (factor IX deficiency), and the test for detecting lupus anticoagulant (LA) in antiphospholipid syndrome. Its complementarity with the prothrombin time (PT) — which assesses the extrinsic pathway (factor VII + common pathway) — allows for a systematic approach to coagulation disorders: an isolated prolongation of PT suggests a factor VII deficiency, an isolated prolongation of APTT suggests a problem with the intrinsic pathway, and a prolongation of both suggests a defect in the common pathway or a multiple deficiency (liver failure + DIC + oral anticoagulants).
Reference values and preanalytical conditions
- Normal values: TCA 25 to 38 seconds (variable depending on the reagent used by the laboratory) + always compare to the laboratory control TCA + TCA/control ratio > 1.2 = significant prolongation + ratio > 2.5 = major prolongation
- Critical pre-analytical conditions: Citrated tube (blue cap) filled exactly to the calibration mark (blood/citrate ratio of 9/1 is essential) + if tube is underfilled → false elevation of aPTT due to excess citrate + rapid transport to the laboratory (maximum 4 hours at room temperature) + centrifugation at 2,500 g x 15 minutes + do not freeze if analyzed immediately
- Causes of prolonged aPTT: underfilled tube + hemolysis of the sample + presence of residual heparin in a venous line (contaminated sample) + significant lipemia + hyperbilirubinemia
- Mixing test — interpretation key: If prolonged aPTT → mix patient's plasma (1/1) with normal reference plasma → if aPTT corrects → factor deficiency (normal plasma provides the missing factor) → if no correction (aPTT remains prolonged) → circulating inhibitor (lupus anticoagulant + anti-factor antibody)
Causes of prolonged aPTT
| Cause | Mechanism and concerned factor | Mixing tests and complementary examinations |
|---|---|---|
| Hemophilia A (factor VIII deficiency) | X-linked hereditary factor VIII deficiency → prolonged APTT + normal PT + male patient + joint bleeding (hemarthrosis) + muscle bleeding + mucosal bleeding + severe hemophilia: factor VIII < 1 1PT3T + moderate 1–5 1PT3T + mild 5–40 1PT3T | Correction with mixing test (deficiency) → Factor VIII assay confirms + treatment: recombinant or plasma-derived Factor VIII concentrate + prophylactic emicizumab (Hemlibra®) |
| Hemophilia B (Factor IX deficiency) | X-linked hereditary deficiency in factor IX → prolonged aPTT + normal PT + clinical presentation identical to hemophilia A but less frequent (1 in 5 hemophilias) | Correction with mixed testing → Factor IX dosage confirms + treatment: Factor IX concentrates + fitusiran + concizumab (new subcutaneous therapies) |
| Von Willebrand disease (type 1 + 2 + 3) | Von Willebrand factor (vWF) transports and protects factor VIII in circulation → vWF deficiency → secondary reduction in factor VIII → prolonged aPTT (not always—can be normal in mild forms) + mucocutaneous bleeding (nosebleeds + heavy menstrual bleeding + bleeding gums) | TCA variable + prolonged bleeding time + vWF antigen assay + vWF ristocetin activity (cofactor) + factor VIII + multimer electrophoresis + mixing study: correction (deficiency) + treatment: desmopressin (DDAVP) if type 1 responder + vWF concentrates |
| Anticoagulant lupus (LA — antiphospholipid syndrome) | IgG or IgM antibodies directed against phospholipids + phospholipid-binding proteins (beta-2-glycoprotein I + prothrombin) → prolong aPTT in vitro (paradox: anticoagulant in vitro but prothrombotic in vivo) → arterial and venous thromboses + recurrent abortions | No correction to the mixing test (inhibitor) + confirmation by specific tests LA: diluted Russell viper venom time (dRVVT) + LA-sensitive aPTT + persistence at 12 weeks interval to confirm APSL + ANA + anti-cardiolipin + anti-beta2GP1 |
| Unfractionated heparin (UFH) therapeutic | Unfractionated heparin potentiates antithrombin III → inhibition of factors IIa (thrombin) + Xa → prolongation of aPTT used as a parameter for therapeutic monitoring + therapeutic target: aPTT patient/control ratio 1.5 to 2.5 depending on protocols | Obvious clinical context (patient on UFH) + NO complete correction on mixing test if high concentration + antidote: IV protamine sulfate (1 mg per 100 IU UFH administered in the last 4 hours) |
| Deficiency in contact factors (XII + XI + prekallikrein + HMWK) | Factor XII deficiency → Very prolonged aPTT (sometimes > 200 sec) + NO bleeding risk (factor XII is not essential for in vivo hemostasis) + paradoxically associated with increased thrombotic risk (factor XII participates in fibrinolysis) + Factor XI deficiency → moderate bleeding risk (tendency to post-surgical bleeding) | Slightly prolonged TCA but no hemorrhagic syndrome = consider Factor XII deficiency + correction on mixing test + contact factor assay + Factor XII deficiency requires no treatment |
| Acquired anti-factor VIII inhibitor | Acquired IgG antibodies against factor VIII → acquired hemophilia A + more often in the elderly + postpartum + autoimmune diseases + cancers → severe spontaneous bleeding | Extended TCA + no mixing test correction + very low Factor VIII + inhibitor titer (Bethesda units) + treatment: bypassing agents (eptacog alfa rFVIIa + FEIBA) + emicizumab + immunosuppressants (rituximab + cyclophosphamide + corticosteroids) to eliminate the antibody |
| Disseminated intravascular coagulation | Consumption of all coagulation factors → prolonged aPTT + prolonged PT + thrombocytopenia + hypofibrinogenemia + very high D-dimers + context: sepsis + major trauma + massive transfusion + obstetrical complications | TCA + TP both prolonged + fibrinogen very low + D-dimers very high + treatment of cause + fresh frozen plasma transfusion + fibrinogen concentrate + PCC if major hemorrhage |
ℹ️
The paradox of lupus anticoagulant (LA): an in vitro prolonged aPTT but an in vivo THROMBOTIC (not hemorrhagic) risk. Lupus anticoagulant prolongs aPTT by interfering with test phospholipids, but in circulation it promotes thrombosis by activating platelets and the endothelium. An isolated prolonged aPTT in a patient without bleeding + a history of thrombosis or miscarriage should systematically suggest lupus anticoagulant and antiphospholipid syndrome — not a hemorrhagic risk to be corrected.
TCA in unfractionated heparin monitoring
- Standard monitoring protocol: TCA baseline before initiation, then every 6 hours until stable target reached, then every 24 hours. Usual target: patient/control TCA ratio of 1.5 to 2.5 (or 60 to 100 seconds depending on hospital center protocols). Adjust IV infusion dose according to validated nomograms.
- TCA limits for LMWH: Significant inter-laboratory variability depending on the reagent used + anti-Xa assays are sometimes preferred (more reproducible) in certain populations (obesity + pregnancy + renal insufficiency) + LMWH (low molecular weight heparin) ARE NOT monitored by aPTT (their effect is too weak to significantly prolong aPTT at standard prophylactic or therapeutic doses) → monitor by anti-Xa if necessary (CKD + pregnancy + obesity)
TCA and direct thrombin inhibitors (dabigatran)
- Dabigatran (Pradaxa®): direct thrombin (IIa) inhibitor → prolongs aPTT in a dose-dependent manner + but aPTT is not a reliable or accurate monitoring tool for dabigatran (non-linear relationship) → use diluted thrombin time (dTT) or anti-IIa chromogenic assay for precise quantification + a normal aPTT excludes a significant therapeutic concentration of dabigatran + a markedly prolonged aPTT suggests accumulation (renal insufficiency + overdose) → plasma dabigatran level
Situations requiring urgent hematological consultation
A significantly prolonged aPTT (ratio > 2.5) incidentally discovered in a patient with no known anticoagulant treatment and no current bleeding context, or a prolonged aPTT with abnormal bleeding (hemarthroses + spontaneous deep bleeding), requires urgent hematological evaluation to identify the cause (undiagnosed hemophilia + acquired hemophilia + lupus anticoagulant) and initiate appropriate treatment. A significantly prolonged aPTT with uncorrected mixing studies and acute bleeding presentation is a bleeding emergency — call 911.
For the interpretation of a prolonged PTT, the prescription of the mixing test + coagulation factor assays and hematological orientation, Clinique Omicron offers medical consultations at its service points in Quebec and via telemedicine. To make an appointment, visit cliniqueomicron.ca.
Consult at Clinique Omicron
Clinique Omicron's nurse practitioners (NPs) and physicians prescribe and interpret the aPTT as part of pre-operative assessment, anticoagulant monitoring, investigation of unexplained bleeding syndrome, and investigation of an incidental finding of prolonged clotting time. They order mixing studies and factor assays if necessary, and refer patients to hematology for congenital or acquired factor deficiencies and antiphospholipid syndrome. Consultations are available at several service locations in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not replace the advice of a doctor or hematologist. The interpretation of a prolonged aPTT always requires the complete clinical context, correlation with PT-INR, platelet count, fibrinogen, and mixing studies — a systematic approach is essential to identify the cause and adapt treatment.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.